Compare IHRT & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | VYGR |
|---|---|---|
| Founded | 1974 | 2013 |
| Country | United States | United States |
| Employees | N/A | 141 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.5M | 193.5M |
| IPO Year | 2019 | 2015 |
| Metric | IHRT | VYGR |
|---|---|---|
| Price | $2.35 | $2.88 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.25 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 432.7K | 373.2K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,864,991,000.00 | $10,135,000.00 |
| Revenue This Year | $9.96 | $34.04 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.27 | N/A |
| 52 Week Low | $2.32 | $2.94 |
| 52 Week High | $6.56 | $5.55 |
| Indicator | IHRT | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.48 |
| Support Level | N/A | $2.96 |
| Resistance Level | N/A | $3.30 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 26.72 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.